We did it! The first approved medication for bronchiectasis Brensocatib approved by the FDA in the United States. A great day for patients and the scientific community that made this happen. Thank you Insmed, all investigators and participants https://t.co/T5XthQtIRI

Check out the new ATS guidelines for community-acquired pneumonia 👇

Effects of Dupilumab on small airways from VESTIGE RCT : Improved small airways function with Dupi due to direct effect on ASM (IL4/13 but not IL5 expression) and dissolution of mucus plugs https://t.co/H9sygocquB

#NewProfilePic

Today is #WorldAsthmaDay! Summer isn’t always an easy season when you have a lung condition. Things like hay fever and hot weather can make breathing more difficult and stop you doing the things you love. This summer we want to inspire you with ways to achieve your goals ☀️

This is excellent news and long overdue. I’m sure it will tempt many who have moved to secondary/tertiary care roles and who are not necessarily valued financially for undertaking this level of practice to come back to primary/community care.

Today’s the day where we finally get to present the 1st National joint NICE/BTS/SIGN asthma guidelines that myself and the other fabulous committee members have been working on for the last 3 years. A little bit excited and a little bit nervous. Let’s see how they’re received.

Here is a link below to a talk I gave today for the British Thoracic Society Improving Asthma Amanagment Short Course Diagnosing asthma – all the pieces of the jigsaw I have decided to make this open access-Enjoy https://t.co/ukh8BGtbn8 via @YouTube

Once again a brilliant presentation and overview from @ProfJDChalmers on bronchiectasis at the West Country Chest Society meeting

Fabulous session this morning on breathlessness in the elite athlete from @Breathe_to_win at the West Country Chest Society meeting.

Is remission in COPD possible? When comparing criteria as in other conditions then the opinion is that it can be but we are not there yet @ERScongress

#ERS2024 Clinical year in review: COPD & CVD. 🔶 CVD reduces symptom control in COPD 🔶 MI risk increased by 2-5% after # #AECOPD - Highest risk in the first month, sustained for a year 🔶 Limited and conflicting evidence of ICS on reducing CVD risk

Young people who vape perform worse than non-vapers in tests designed to measure their capacity for exercise, according to a study presented at the #ERSCongress today Read the full story: https://t.co/yjlQZ8DbzL

Professor Fabbri presenting the fact that COPD is not a stand alone condition. @ERScongress

#respisbest #ERS2024 Guideline "Symptom management for patients with serious #Respiratory illness" 2/2 Opiates and #breathlessness : 🌟 lab based studies +ve for acute exercise & SOB 🌟 no benefit of Opiates on #breathlessness, hrqol or cough 🌟 AEs & events Not recommended

#respisbest #ERS2024 #ERScongress Guideline "Symptom management for patients with serious #Respiratory illness" 1/2 🌟 patient voice embedded ✅️ breathlessness services ✅️ exercise for fatigue ✅️ hand held fan ? Supplemental oxygen ✅️ breathing exercises NUANCE +++ 👇

Lovely presentation @EuroRespSoc methotrexate as effective as prednisolone at 24wks in Dutch cohort @SarcoidosisUK @ild_inn

Great kick off to #ERSCongress with the clinical year in review on cardiovascular risk in #COPD.

Interesting session this morning on the AIR approach in asthma @ERScongress. Overall the evidence is good but barriers in the way.